Is it safe to initiate lithium therapy in a patient taking esomeprazole (Nexium) 40 mg twice daily, diltiazem hydrochloride 240 mg daily, meloxicam (Mobic) 7.5 mg daily, atorvastatin 40 mg daily, inhaled fluticasone propionate (Flovent) as needed, fluticasone nasal spray 50 mcg two puffs daily, a rescue inhaler, and testosterone, with controlled hypertension, asthma, acid reflux, and recent glaucoma surgery?

Lithium Initiation Safety Assessment

Yes, lithium can be initiated in this patient, but meloxicam (Mobic) and diltiazem require careful management due to significant drug-drug interactions that can elevate lithium levels and increase toxicity risk.

Critical Drug Interactions Requiring Action

Meloxicam (Mobic) - High Priority Concern

Meloxicam moderately increases lithium plasma concentrations by approximately 21% for steady-state levels and 16% for peak concentrations 1. While this study in healthy volunteers suggested the magnitude was "of low clinical relevance," this was in controlled conditions—real-world clinical practice shows NSAIDs are significant contributors to lithium toxicity 2.

• Action Required: NSAIDs should be avoided in patients taking lithium 3, 4. Consider discontinuing meloxicam or switching to acetaminophen for arthritis pain management.
• If meloxicam must be continued: Initiate lithium at a lower starting dose, monitor lithium levels weekly initially, and watch closely for signs of toxicity (tremor, confusion, ataxia, nausea).
• Mechanism: NSAIDs reduce renal lithium clearance by decreasing glomerular filtration and affecting electrolyte exchange in the nephron 5.

Diltiazem - Moderate Concern

Diltiazem is a calcium channel blocker that can affect lithium levels, though the evidence is less direct than with NSAIDs. The primary concern is that diltiazem may contribute to neurotoxicity when combined with lithium, even without changes in lithium pharmacokinetics 5.

• Action Required: Continue diltiazem but monitor closely for neurotoxic symptoms (confusion, tremor, ataxia, slurred speech).
• Note: Lisinopril was already stopped by the provider, which is appropriate as ACE inhibitors can impair lithium elimination and increase toxicity risk 6.

Medications Without Significant Lithium Interactions

Esomeprazole (Nexium) - No Concern

No clinically significant interaction between esomeprazole and lithium has been documented. The case report of rhabdomyolysis involved atorvastatin with esomeprazole and clarithromycin 7, not lithium. Nexium can be continued without dose adjustment 8.

Atorvastatin - No Direct Concern

Atorvastatin and diltiazem combination is reasonable 9, resulting in only minor increases in statin exposure. No direct lithium interaction exists. Continue current dose.

Inhaled Fluticasone (Flovent) and Nasal Fluticasone - No Concern

These are topical corticosteroids with minimal systemic absorption 10. No interaction with lithium. Continue as prescribed.

Testosterone - No Concern

No documented interaction with lithium. Continue therapy.

Monitoring Protocol for Lithium Initiation

1. Baseline Assessment:

   • Serum creatinine and eGFR (critical given diltiazem use and controlled hypertension)
   • Electrolytes (sodium, potassium)
   • Thyroid function (TSH, free T4)
   • Pregnancy test if applicable
   • ECG (given diltiazem use)

2. Lithium Level Monitoring:

   • Check lithium level 5-7 days after initiation
   • Target therapeutic range: 0.6-0.8 mmol/L for maintenance 6
   • Weekly levels initially, then every 2-4 weeks until stable
   • Check level 12 hours post-dose (trough level)

3. Renal Function Monitoring:

   • Check creatinine and electrolytes with each lithium level initially
   • Critical: Any medication that alters glomerular filtration or electrolyte exchange can affect lithium clearance 5

4. Clinical Monitoring:

   • Watch for early toxicity signs: tremor, nausea, diarrhea, confusion
   • Monitor for dehydration (especially with recent glaucoma surgery)
   • Ensure adequate hydration and stable sodium intake

Common Pitfalls to Avoid

• Do not ignore the meloxicam: This is the highest-risk medication in this regimen. The 7.5 mg daily dose may seem low, but even this can significantly affect lithium clearance 1.
• Antibiotics: If this patient develops an infection requiring antibiotics, be aware that antibiotics are associated with elevated lithium levels 2. Monitor lithium levels if antibiotics are prescribed.
• Dehydration risk: Recent glaucoma surgery and controlled hypertension suggest this patient may be older. Ensure adequate fluid intake, as dehydration dramatically increases lithium toxicity risk 11.
• Irregularity in medication adherence: Irregular lithium dispensing patterns are associated with elevated lithium levels 2. Emphasize consistent daily dosing.

Recommended Action Plan

Before initiating lithium:

1. Discontinue meloxicam or reduce to lowest effective dose with very close monitoring
2. Obtain baseline labs (creatinine, electrolytes, TSH, ECG)
3. Counsel patient on maintaining consistent hydration and sodium intake
4. Warn patient about signs of lithium toxicity

After lithium initiation:

1. Start with standard or slightly reduced lithium dose given meloxicam use
2. Check lithium level at 5-7 days
3. Monitor renal function and electrolytes weekly initially
4. Adjust dose to achieve 0.6-0.8 mmol/L range
5. Watch for neurotoxicity symptoms given diltiazem co-administration